Venture capital fundraising by biopharmaceutical companies totaled $5.7bn during the first quarter of 2020 – the second-highest amount ever raised by the industry in a single quarter – as private drug developers finalized financings that most likely were in the works before the COVID-19 pandemic shrank the values of publicly traded companies.
Biopharma venture capital investment is sure to feel an impact over the course of 2020 as investors hold on to...






